Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Colorcon
Harvard Business School
Express Scripts
McKesson

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR CADUET


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Caduet

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00150384 ↗ Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population Completed Pfizer Phase 4 2004-07-01 The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
NCT00150384 ↗ Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population Completed Pfizer's Upjohn has merged with Mylan to form Viatris Inc. Phase 4 2004-07-01 The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
NCT00332761 ↗ Caduet in an Untreated Subject Population Completed Pfizer Phase 4 2006-06-01 The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.
NCT00332761 ↗ Caduet in an Untreated Subject Population Completed Pfizer's Upjohn has merged with Mylan to form Viatris Inc. Phase 4 2006-06-01 The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Caduet

Condition Name

Condition Name for Caduet
Intervention Trials
Hypertension 7
Dyslipidemia 3
Hypercholesterolemia 3
Angina Pectoris 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Caduet
Intervention Trials
Hypertension 5
Dyslipidemias 4
Hypercholesterolemia 3
Angina Pectoris 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Caduet

Trials by Country

Trials by Country for Caduet
Location Trials
United States 66
Japan 8
Mexico 4
Venezuela 3
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Caduet
Location Trials
Georgia 3
California 3
Virginia 3
Texas 3
Tennessee 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Caduet

Clinical Trial Phase

Clinical Trial Phase for Caduet
Clinical Trial Phase Trials
Phase 4 9
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Caduet
Clinical Trial Phase Trials
Completed 9
Unknown status 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Caduet

Sponsor Name

Sponsor Name for Caduet
Sponsor Trials
Pfizer 8
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 7
Dr. Reddy's Laboratories Limited 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Caduet
Sponsor Trials
Industry 17
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Medtronic
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.